Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C

Gastroenterologie Clinique et Biologique

Volumn 29, Issue 4, 2005, Pages 339-345

  Moncoucy, Xavier ^a   Leymarie, Florence ^b   Delemer, Brigitte ^a   Lévy, Stéphane ^a   Bernard Chabert, Brigitte ^a   Bouché, Olivier ^a   Jolly, Damien ^b   Diebold, Marie Danièle ^a   Cadiot, Guillaume ^a   Thiéfin, Gérard ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b HÔPITAL MAISON BLANCHE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMANTADINE; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LEVOTHYROXINE; MICROSOME ANTIBODY; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CHRONIC HEPATITIS; DISEASE COURSE; FEMALE; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; THYROID DISEASE; THYROIDITIS; THYROTROPIN BLOOD LEVEL;

EID: 20844458424     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(05)80778-X     Document Type: Article

References (33)

1. Cacoub P, Renou C, Rosenthal E, Cohen P, Louvry I, Loustaud-Rotti V, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 malades. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hépatite C. Medicine (Baltimore) 2000;79:47-56.
2. Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M, et al. High prevalence of serological markers of autoimmunity in malades with chronic hepatitis C. Hepatology 1995;21:613-9.
3. Lunel F. Hépatite C et anomalies immunologiques. Gastroenterol Clin Biol 1994;18:829-38.
4. Obermayer-Straub P, Manns MP. Hepatitis C and D, retroviruses and autoimmune manifestations. J Autoimmun 2001;16:275-85.
5. Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19:841-8.
6. Paleron D, Hartmann DJ, Duclos-Vallée JC, Jouanolle H, Beaugrand M. Latent autoimmune thyroid disease in malades with chronic HCV hepatitis. J Hepatol 1992;16:244-5.
7. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, et al. High prevalence of thyroid auto-antibodies in a prospective series of malades with chronic hepatitis C before Interferon therapy. Hepatology 1993;18:253-7.
8. Gorez E, Nakib I, Larbre H, Schneider N, Schvartz C, Delisle MJ, et al. Lack of epidemiological evidence for a link between thyroid auto-immune disease and hepatitis C virus infection. J Hepatol 1997;26:738-9.
9. Nduwayo L, Bacq Y, Valat C, Goudeau A, Lecomte P. Fonction et auto-immunité thyroïdienne chez 215 malades séropositifs pour le virus de l'hépatite C. Ann Endocrinol (Paris) 1998;59:9-13.
10. Blot E, Kerleau JM, Levesque H, Heron F, Menard JF, Buffet-Janvresse C, et al. Les dysthyroïdies auto-immunes liées au virus C existent-elles? Réflexions à propos d'une étude contrôlée de 58 sujets consécutifs. Rev Med Interne 1999;20:220-5.
11. Vial T, Bailly F, Descotes J, Trepo C. Effets secondaires de l'interféron alpha. Gastroenterol Clin Biol 1996;20:462-89.
12. Baudin E, Marcellin P, Pouteau M, Colas-Linhart N, Le Floch JP, Lemonnier C, et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol 1993;39:657-61.
13. Benelhadj S, Marcellin P, Castelnau C, Colas-Linhart N, Benhamou JP, Erlinger S, et al. Incidence of dysthyroidism during interferon therapy in chronic hepatitis C. Horm Res 1997;48:209-14.
14. Berris B, Feinman SV. Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis. Dig Dis Sci 1991;36:1657-60.
15. Carella C, Amato G, Biondi B, Rotondi M, Morisco F, Tuccilo C, et al. Longitudinal study of antibodies against thyroid in malades undergoing interferon α therapy for HCV chronic hepatitis. Horm Res 1995;44:110-4.
16. Deutsch M, Dourakis S, Manesis E, Gioustozi A, Hess G, Horsch A, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alpha therapy. Hepatology 1997;26:206-10.
17. Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, Chen SC, et al. Virologic factors related to interferon-α-induced thyroid dysfunction in malades with chronic hepatitis C. Eur J Endocrinol 2000;142:431-7.
18. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alpha. Gastroenterology 1992;102:2155-60.
19. Marazuela M, Garcia-Buey L, González-Fernández B, Garcia-Monzón, Arranz A, Borque M.J, et al. Thyroid autoimmune disorders in malades with chronic hepatitis C before and during interferon-α therapy. Clin Endocrinol 1996;44:635-42.
20. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, et al. Multiple changes in thyroid function in malades with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996;172:482-7.
21. Imagawa A, Itoh N, Hanafusa T, Oda Y, Waguri M, Miyagawa JI, et al. Autoimmune endocrine disease induced by recombinant interferon α therapy for chronic active type C hepatitis. J Clin Endocrinol Metabol 1995;80:922-6.
22. Watanabe U, Hashimoto E, Hishamitsu T, Obata H, Hayashi N. The risk factors for development of thyroid disease during interferon-α therapy for chronic hepatitis C. Am J Gastroenterol 1994;89:399-403.
23. Mekkakia-Benhabib C, Marcellin P, Colas-Linhart N, Castelnau C, Buyck C, Erlinger S, et al. Histoire naturelle des dysthyroïdies survenant sous interféron dans le traitement des hépatites chroniques C. Ann Endocrinol 1996;57:419-27.
24. Kiehne K, Kloehn S, Hinrichsen H, Gallwitz B, Mönig H. Thyroid autoantibodies and thyroid dysfunction during treatment with interferon-α for chronic hepatitis C. Endocrine 1997;6:231-4.
25. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, et al. J. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998;158:1445-8.
26. Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo, et al. Long-term outcome of interferon-α-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001;86:1925-9.
27. Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. New Engl J Med 1996;335:99-107.
28. Rapoport B, McLachlan SM. Thyroid peroxydase antibodies. In: Peter JB, Schoenfeld Y, eds. Autoantibodies. New York: Elsevier. 1996;816-21.
29. Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002;36:1280-4.
30. Parana R, Cruz M, Lyra L, Cruz T. Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. J Viral Hepatol 2000;7:393-5.
31. Carella C, Mazziotti G, Morisco F, Rotondi M, Cioffi M, Tuccillo C, et al. The addition of ribavirin to interferon-alpha therapy in malades with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 2002;146:743-9.
32. Broussolle C, Steineur MP, Bailly F, Zoulim F, Trépo C. Infection par le virus de l'hépatite C et pathologies thyroïdiennes. Rev Med Interne 1999;20:766-73.
33. Conférence de Consensus «Traitement de l'Hépatite Chronique C». Texte du consensus (Maison de la Chimie, 27-28 février 2002). Gastroenterol Clin Biol 2002;26: B302-11.